Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.56 |
| ▸ | ENTPD2 | Q9Y5L3 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525149 | 1.00 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL27939255 | 0.95 | P2RY14 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29885070 | 0.89 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL8772850 | 0.88 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL18877356 | 0.88 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6913156 | 0.87 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL14384430 | 0.87 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL22124733 | 0.87 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6530467 | 0.87 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Ammonia Solution, Strong SCHEMBL28250466 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215467-A1 | L-THREONINE TRANSALDOLASES AND USES THEREOF | UNIVERSITY OF DELAWARE (US) | 2025-07-03 | — | — | US | claimed |
| WO-2023178318-A2 | L-THREONINE TRANSALDOLASES AND USES THEREOF | KUNJAPUR ADITYA (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2008039525-A2 | CADHERIN ANTAGONISTS IN COMBINATION WITH ANTICANCER AGENTS FOR USE IN CANCER TREATMENT | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-04-03 | — | — | WO | claimed |
| WO-2004022152-A9 | RADIOTHERAPY METHOD USING X-RAYS | NANODAYNAMICS INC (US) | 2004-06-17 | — | — | WO | claimed |
| EP-0951566-B1 | A METHOD OF PURIFYING DNA | UNIV HEIDELBERG (DE) | 2002-12-18 | — | — | EP | claimed |
| US-20250215467-A1 | L-THREONINE TRANSALDOLASES AND USES THEREOF | UNIVERSITY OF DELAWARE (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2024123794-A2 | A T CELL RECEPTOR RECOGNIZING A HER2 MUTATION PRESENTED ON HLA-A*02:01 AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4373516-A1 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING FANCI, RAD51, AND PBK ANTIGENS AND METHODS OF USE | Board of Regents, The University of Texas System (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4363454-A1 | POLYPEPTIDES TARGETING CD70-POSITIVE CANCERS | Board of Regents, The University of Texas System (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024069589-A1 | CANNABINOID ANALOGS AND METHODS OF USE FOR TREATMENT AND PREVENTION OF CANCER | BLACKSTONE THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073528-A1 | DESIGN AND UTILIZATION OF GENE TARGETING ANTIBODY FUSION PROTEINS TO PERFORM IN VIVO THERAPEUTIC GENE EDITING | BAYLOR COLLEGE OF MEDICINE (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024054897-A1 | METHODS FOR TREATING CANCER WITH HYPERACTIVE ADAR ENZYMES | THE UNIVERSITY OF CHICAGO (US) | 2024-03-14 | — | — | WO | disclosed |
| US-5762918-A | ANGIOGENESIS | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1998015649-A1 | A METHOD OF PURIFYING DNA | Universität Heidelberg (DE) | 1998-04-16 | — | — | WO | disclosed |
| WO-1997048391-A9 | METHODS AND COMPOSITIONS COMPRISING R-IBUPROFEN | — | 1998-04-09 | — | — | WO | disclosed |
| WO-1997048391-A2 | METHODS AND COMPOSITIONS COMPRISING R-IBUPROFEN | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5676978-A | ANTITUMOR AGENT; SYNERGISTIC MIXTURE | AMIRA, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5474765-A | Drug delivery; heparin/steroid conjugates; selectively hydrolyzable linkage e.g, an acid labile or enzyme-sensitive bond; angiogenesis inhibitors; anticarcinogenic,-arthritic and diabetic agents | UT SW MEDICAL CTR AT DALLAS (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0181902-A1 | NEW COMPOSITIONS OF LIPOSOMES HAVING A SPECIFIC ACTION WITH REGARD TO THE PROLIFERATION OF GIVEN CELLS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1986-05-28 | — | — | EP | disclosed |
| WO-1985005453-A1 | NEW COMPOSITIONS OF LIPOSOMES HAVING A SPECIFIC ACTION WITH REGARD TO THE PROLIFERATION OF GIVEN CELLS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M (FR) | 1985-12-05 | — | — | WO | disclosed |